IBA (Ion Beam Applications S.A.) launched the new Visicoil Twin-Line fiducial marker at the annual meeting of the 2012 American Society for Radiation Oncology (ASTRO). This innovative new solution includes two Visicoil markers separated by a bioresorbable spacer. It offers all the clinically proven benefits of VISICOIL but “automatically” aids the physician to place both markers with a consistent 2 cm “Center to Center” distance with a single implantation needle.
It offers clinical benefits associated with fewer and smaller needles; less bleeding and edema along with improved patient comfort. IBA’s patented Visicoil linear fiducial markers are an important component in the effort to increase targeting accuracy in radiation therapy applications such as IGRT, IMRT, CRT, PT and SBRT.
For more information, visit www.visicoil.com.
April 10, 2026 
